On March 13, Aidea Pharma announced an exciting news: the company has received a Good Manufacturing Practice (GMP) Certificate issued by the Zanzibar Food and Drug Agency (ZFDA), marking its first overseas GMP certificate—a milestone of profound significance.

Following the official notification of an on-site inspection in November 2024, Aidea Pharma conducted a comprehensive review of manufacturing, packaging, utilities, quality control, and quality assurance systems. A stringent improvement plan was formulated, with dedicated personnel assigned to ensure the full implementation of measures.

From December 16 to 18, 2024, ZFDA inspectors conducted a three-day GMP compliance on-site audit focusing on the production of oral solid dosage forms. Aidea Pharma demonstrated efficient production management and rigorous quality control capabilities, earning high praise from the inspectors.

Aidea Pharma has long been committed to building high-standard quality systems, continuously benchmarking against the world’s most advanced pharmaceutical standards. The GMP certificate from ZFDA not only confirms full compliance of the company’s production facilities with ZFDA requirements for manufacturing oral solid dosage forms but also establishes a critical pathway for introducing Aidea’s anti-HIV innovative drugs, including Ainuomiti Tablets, into the Zanzibar market.

The African market serves as a pivotal component of Aidea Pharma’s overseas commercialization strategy for its anti-HIV innovative drugs. The GMP Certificate from ZFDA will significantly drive the company’s business growth in Zanzibar and across African markets. Leveraging this milestone, Aidea Pharma will further strengthen pharmaceutical R&D and production governance, continuously enhance product quality and customer satisfaction, and deliver safer, more effective medications to customers.